Urofollitropin is primarily used in fertility treatments to stimulate ovarian follicular growth in women who have difficulty conceiving due to ovulatory disorders. It is often administered as part of assisted reproductive technologies, such as in vitro fertilization (IVF), to promote the development of multiple follicles, thereby increasing the chances of successful egg retrieval. Additionally, it is used in combination with other hormones, like human chorionic gonadotropin (hCG), to trigger ovulation. In men, urofollitropin can be employed to treat hypogonadotropic hypogonadism, a condition characterized by low testosterone levels, by stimulating spermatogenesis. Its application is carefully monitored through hormonal assays and ultrasounds to ensure optimal dosing and minimize risks such as ovarian hyperstimulation syndrome (OHSS).